Clinical Trial Update: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial of ES135 for spinal cord injury has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• ES135

Snippet

Sponsor: Eusol Biotech Co., Ltd. | Conditions: Spinal Cord Injuries | Phase 3 | Status: SUSPENDED